The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ozhimalov I.D.

Lomonosov Moscow State University

Gorbacheva A.M.

Endocrinology Research Centre

Eremkina A.K.

Endocrinology Research Centre

Mokrysheva N.G.

Endocrinology Research Centre

Features of the bone metabolism in primary hyperparathyroidism

Authors:

Ozhimalov I.D., Gorbacheva A.M., Eremkina A.K., Mokrysheva N.G.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2024;27(9): 130‑137

DOI: 10.17116/profmed202427091130

Views: 321

Downloaded: 2

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Ozhimalov ID, Gorbacheva AM, Eremkina AK, Mokrysheva NG. Features of the bone metabolism in primary hyperparathyroidism. Russian Journal of Preventive Medicine. 2024;27(9):130‑137. (In Russ.)
https://doi.org/10.17116/profmed202427091130

Подписка 2025 (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Close metadata
Recommended articles:
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Transoral endo­scopic para­thyroidectomy, vestibular access (TOEPVA): a new word in dome­stic para­thyroid gland surgery. Endo­scopic Surgery. 2024;(1):26-35
A differentiated approach to tari­ffs for inpa­tient examination and treatment of primary hype­rparathyroidism on the example of bundled payment method. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):47-59
Biotechnological method for bone tissue reco­very: theoretical basis and clinical application. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):12-17
The role of immu­nohistochemical examination in the differential diagnosis of atypical tumors and carcinomas of para­thyroid glands. Russian Journal of Archive of Pathology. 2024;(4):5-12

Primary hyperparathyroidism (PHPT) is an endocrine disease caused by autonomous hyperproduction of parathyroid hormone by the primary altered parathyroid glands. Long-term PHPT leads to several complications, the most common being the disorders of bone metabolism and decreased bone mineral density (BMD). Dual-energy X-ray absorptiometry (DXA) is the «gold standard» for detecting BMD. Parathyroidectomy remains the only method of PHPT pathogenetic treatment, resulting in independent BMD growth. Bisphosphonates, denosumab, calcimimetics, and vitamin D preparations can reduce the risk of PHPT complications, including bone complications, if surgery is impossible.

Keywords:

primary hyperparathyroidism
bone remodeling
resorption
dual-energy X-ray absorptiometry
mineral density
bone
parathyroidectomy
antiresorptive therapy

Authors:

Ozhimalov I.D.

Lomonosov Moscow State University

Gorbacheva A.M.

Endocrinology Research Centre

Eremkina A.K.

Endocrinology Research Centre

Mokrysheva N.G.

Endocrinology Research Centre

Received:

25.01.2024

Accepted:

23.04.2024

List of references:

  1. Schaffler MB, Cheung WY, Majeska R, et al. Osteocytes: master orchestrators of bone. Calcified Tissue International. 2014;94(1):5-24.  https://doi.org/10.1007/S00223-013-9790-Y
  2. Tobeiha M, Moghadasian MH, Amin N, et al. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. BioMed Research International. 2020;2020:6910312. https://doi.org/10.1155/2020/6910312
  3. Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocrine Pathology. 2022;33(1):64-89.  https://doi.org/10.1007/S12022-022-09709-1
  4. Centeno PP, Herberger A, Mun HC, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nature Communications. 2019;10(1):4693. https://doi.org/10.1038/S41467-019-12399-9
  5. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. The Journal of Clinical Investigation. 2007; 117(12):4003-4008. https://doi.org/10.1172/JCI32409
  6. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research. 2004;19(3):429-435.  https://doi.org/10.1359/JBMR.0301264
  7. Locklin RM, Khosla S, Turner RT, et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. Journal of Cellular Biochemistry. 2003;89(1):180-190.  https://doi.org/10.1002/JCB.10490
  8. Kousteni S, Bilezikian JP. The cell biology of parathyroid hormone in osteoblasts. Current Osteoporosis Reports. 2008;6(2):72-76.  https://doi.org/10.1007/S11914-008-0013-9
  9. Baylink D, Wergedal J, Stauffer M. Formation, mineralization, and resorption of bone in hypophosphatemic rats. The Journal of Clinical Investigation. 1971;50(12):2519-2530. https://doi.org/10.1172/JCI106752
  10. Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. International Journal of Molecular Sciences. 2022; 23(3):1376. https://doi.org/10.3390/IJMS23031376
  11. Dedov II, Melnichenko GA, Mokrysheva NG, et al. Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients. Jendokrinnaja hirurgija. 2023;16(4):5-54. (In Russ.). https://doi.org/10.14341/SERG12790
  12. Belaya ZhE, Belova KYu, Biryukova EV, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporoz i osteopatii. 2021;24(2):4-47. (In Russ.). https://doi.org/10.14341/OSTEO12930
  13. Gorbacheva AM, Bibik EE, Dobreva EA, et al. Structure of metabolic disorders and cardiovascular disease in patients with primary hyperparathyroidism: a single-center retrospective observational study. Russian Journal of Preventive Medicine. 2022;25(8):54-66. (In Russ.). https://doi.org/10.17116/profmed20222508154
  14. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: Biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 1997;21(1):93-99.  https://doi.org/10.1016/S8756-3282(97)00078-1
  15. Castellano E, Attanasio R, Gianotti L, et al. Forearm DXA Increases the Rate of Patients With Asymptomatic Primary Hyperparathyroidism Meeting Surgical Criteria. The Journal of Clinical Endocrinology and Metabolism. 2016;101(7):2729-2732. https://doi.org/10.1210/JC.2016-1513
  16. Piskinpasa H, Dogansen SC, Metin D, et al. The significance of forearm bone mineral density evaluation in determining surgical indications in primary hyperparathyroidism. Annales d’Endocrinologie. 2023;84(1):8-13.  https://doi.org/10.1016/J.ANDO.2022.08.004
  17. Dawson-Hughes B, Tosteson ANA, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis International. 2008;19(4):449-458.  https://doi.org/10.1007/S00198-008-0559-5
  18. Schnitzler CM. Bone quality: a determinant for certain risk factors for bone fragility. Calcified Tissue International. 1993;53 Suppl 1:S27-31.  https://doi.org/10.1007/BF01673398
  19. dos Santos LM, Ohe MN, Pallone SG, et al. Trabecular Bone Score (TBS) in Primary Hyperparathyroidism (PHPT): A Useful Tool? Journal of Clinical Densitometry. 2021;24(4):563-570.  https://doi.org/10.1016/J.JOCD.2021.04.001
  20. Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. European Journal of Endocrinology. 2013;169(2):155-162.  https://doi.org/10.1530/EJE-13-0305
  21. Adams JE. Quantitative computed tomography. European Journal of Radiology. 2009;71(3):415-424.  https://doi.org/10.1016/J.EJRAD.2009.04.074
  22. Wang W, Nie M, Jiang Y, et al. Impaired geometry, volumetric density, and microstructure of cortical and trabecular bone assessed by HR-pQCT in both sporadic and MEN1-related primary hyperparathyroidism. Osteoporosis International. 2020;31(1):165-173.  https://doi.org/10.1007/S00198-019-05186-1
  23. Minisola S, Gianotti L, Bhadada S, et al. Classical complications of primary hyperparathyroidism. Best Practice and Research. Clinical Endocrinology and Metabolism. 2018;32(6):791-803.  https://doi.org/10.1016/J.BEEM.2018.09.001
  24. Shuhart CR, Yeap SS, Anderson PA, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. Journal of Clinical Densitometry. 2019;22(4):453-471.  https://doi.org/10.1016/J.JOCD.2019.07.001
  25. Gonnelli S, Montagnani A, Cepollaro C, et al. Quantitative ultrasound and bone mineral density in patients with primary hyperparathyroidism before and after surgical treatment. Osteoporosis International. 2000;11(3):255-260.  https://doi.org/10.1007/S001980050289
  26. Williams C, Sapra A. Osteoporosis Markers. Treasure Island (FL): StatPearls. StatPearls Publishing; 2023.
  27. Guo CY, Thomas WEG, Wahed Al-Dehaimi A, Assiri AMA, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 1996;81(10):3487-3491. https://doi.org/10.1210/JCEM.81.10.8855790
  28. Ohe MN, Bonanséa TCP, Santos RO, et al. Prediction of bone mass changes after successful parathyroidectomy using biochemical markers of bone metabolism in primary hyperparathyroidism: is it clinically useful? Archives of Endocrinology and Metabolism. 2019;63(4):394-401.  https://doi.org/10.20945/2359-3997000000154
  29. Garton M, Martin J, Stewart A, et al. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. Clinical Endocrinology. 1995;42(5):493-500.  https://doi.org/10.1111/J.1365-2265.1995.TB02668.X
  30. Alonso S, Ferrero E, Donat M, et al. The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. Journal of Endocrinological Investigation. 2012;35(7):640-644. 
  31. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. Joint and muscle involvement in primary hyperparathyroidism. Osteoporoz i osteopatii. 2018; 21(4):10-18. (In Russ.). https://doi.org/10.14341/OSTEO9783
  32. Narayanan N, Palui R, Merugu C, et al. The Risk of Fractures in Primery Hyperparathyroidism: A Meta-Analysis. JBMR Plus. 2021;5(4):e10482. https://doi.org/10.1002/JBM4.10482
  33. Shah VN, Shah CS, Bhadada SK, Sudhakar Rao D. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clinical endocrinology. 2014; 80(6):797-803.  https://doi.org/10.1111/CEN.12398
  34. Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS) — a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 2013;98(5):1963-1970. https://doi.org/10.1210/JC.2012-4255
  35. Mokrysheva NG. Okoloshchitovidnye zhelezy. Pervichnyj giperparatireoz. Moscow: MIA; 2019. (In Russ.).
  36. Mokrysheva NG, Eremkina AK, Elfimova AR, et al. The Russian registry of primary hyperparathyroidism, latest update. Frontiers in Endocrinology. 2023;14:1203437. https://doi.org/10.3389/fendo.2023.1203437
  37. Lu S, Gong M, Zha Y, et al. Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism. The Journal of International Medical Research. 2020;48(10):300060520964698. https://doi.org/10.1177/0300060520964698
  38. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. The Journal of Clinical Endocrinology and Metabolism. 2007;92(5):1687-1692. https://doi.org/10.1210/JC.2006-1836
  39. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. The New England Journal of Medicine. 1999;341(17):1249-1255. https://doi.org/10.1056/NEJM199910213411701
  40. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. The Journal of Clinical Endocrinology and Metabolism. 2008;93(9):3462-3470. https://doi.org/10.1210/JC.2007-1215
  41. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003;327(7414): 530-533.  https://doi.org/10.1136/BMJ.327.7414.530
  42. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings. 2008;83(9):1032-1045. https://doi.org/10.4065/83.9.1032
  43. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings. 2006;81(8):1013-1022. https://doi.org/10.4065/81.8.1013
  44. Leere JS, Karmisholt J, Robaczyk M, et al. Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review. Frontiers in Endocrinology. 2017;8:79.  https://doi.org/10.3389/fendo.2017.00079
  45. Rajput S, Dutta A, Rajender S, et al. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1098841. https://doi.org/10.3389/fendo.2023.1098841
  46. Segula D, Nikolova T, Marks E, et al. Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism. International Journal of Clinical Medicine. 2014;5(14):829-835.  https://doi.org/10.4236/IJCM.2014.514111
  47. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2009;361(8):756-765.  https://doi.org/10.1056/NEJMOA0809493
  48. Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. International Journal of Clinical Practice. 2012;66(12): 1139-1146. https://doi.org/10.1111/IJCP.12022
  49. Ng CH, Chin YH, Tan MHQ, et al. Cinacalcet and primary hyperparathyroidism: systematic review and meta regression. Endocrine Connections. 2020;9(7):743-754.  https://doi.org/10.1530/EC-20-0221
  50. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. The Journal of Clinical Endocrinology and Metabolism. 2009;94(12):4860-4867. https://doi.org/10.1210/JC.2009-1472
  51. Faggiano A, Di Somma C, Ramundo V, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine. 2011;39(3):283-287.  https://doi.org/10.1007/S12020-011-9459-0
  52. Leere JS, Karmisholt J, Robaczyk M, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Diabetes and Endocrinology. 2020;8(5):407-417.  https://doi.org/10.1016/S2213-8587(20)30063-2
  53. Bilezikian JP, Formenti AM, Adler RA, et al. Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? Reviews in Endocrine and Metabolic Disorders. 2021;22(4):1201-1218. https://doi.org/10.1007/S11154-021-09693-7
  54. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2014;99(3):1072-1080. https://doi.org/10.1210/JC.2013-3978
  55. Elfimova AR, Eremkina AK, Rebrova OY, et al. Association of preoperative therapy by native form vitamin D and hypocalcemia after parathyroidectomy in primary hyperparathyroidism patients. Problemy endokrinologii. 2024; 70(1):38-45. (In Russ.). https://doi.org/10.14341/probl13324
  56. Ryhänen EM, Koski AM, Löyttyniemi E, et al. Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study. European Journal of Endocrinology. 2021;185(4):515-524.  https://doi.org/10.1530/EJE-21-0322
  57. Choe HJ, Koo BK, Yi KH, et al. Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism. Journal of Bone and Mineral Metabolism. 2022;40(2): 292-300.  https://doi.org/10.1007/S00774-021-01279-2
  58. Norenstedt S, Pernow Y, Zedenius J, et al. Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study. Journal of Bone and Mineral Metabolism. 2014;29(4):960-967.  https://doi.org/10.1002/JBMR.2102
  59. Aberg V, Norenstedt S, Zedenius J, et al. Health-related quality of life after successful surgery for primary hyperparathyroidism: no additive effect from vitamin D supplementation: results of a double-blind randomized study. European Journal of Endocrinology. 2015;172(2):181-187.  https://doi.org/10.1530/EJE-14-0757

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.